r 56865 has been researched along with butylated hydroxytoluene in 1 studies
| Studies (r 56865) | Trials (r 56865) | Recent Studies (post-2010) (r 56865) | Studies (butylated hydroxytoluene) | Trials (butylated hydroxytoluene) | Recent Studies (post-2010) (butylated hydroxytoluene) |
|---|---|---|---|---|---|
| 72 | 1 | 0 | 155 | 0 | 75 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akima, M; Kato, T; Ohi, N; Ozaki, T; Suzuki, Y; Tamura, K | 1 |
1 other study(ies) available for r 56865 and butylated hydroxytoluene
| Article | Year |
|---|---|
Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 1. 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-(aminopropyl)thiazolidinones.
Topics: Animals; Antioxidants; Aorta, Thoracic; Calcium; Calcium Channel Blockers; Glycine max; Heart; In Vitro Techniques; Lipid Peroxidation; Lipoproteins, LDL; Lipoxygenase; Male; Myocardium; Phenols; Rabbits; Rats; Thiazoles; Thiazolidines; Veratridine | 1998 |